EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

En Route to Targeted Ribosome Editing to Replenish Skin Anchor Protein LAMB3 in Junctional Epidermolysis Bullosa

Bjoern Wimmer, Andreas Friedrich, Katharina Poeltner, Genevieve Edobor, Claudia Mosshammer, Gazmend Temaj, Adriana Rathner, Thomas Karl, Jan Krauss, Joerg von Hagen, Christopher Gerner, Michael Breitenbach und 3 weitere

JID Innovations · 2024-01 · 4 (1) · 100240

DOI: 10.1016/j.xjidi.2023.100240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JID Innovations, 2024-01. Verfasst von Bjoern Wimmer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences and Medical Biology, University of Salzburg, Salzburg, Austria. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Salzburger Landesregierung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe junctional epidermolysis bullosa is a rare genetic, postpartum lethal skin disease, predominantly caused by nonsense/premature termination codon (PTC) sequence variants in LAMB3 gene. LAMB3 encodes LAMB3, the β subunit of epidermal-dermal skin anchor laminin 332. Most translational reads of a PTC mRNA deliver truncated, nonfunctional proteins, whereas an endogenous PTC readthrough mechanism produces full-length protein at minimal and insufficient levels. Conventional translational readthrough-inducing drugs amplify endogenous PTC readthrough; however, translational readthrough-inducing drugs are either proteotoxic or nonselective. Ribosome editing is a more selective and less toxic strategy. This technique identified ribosomal protein L35/uL29 (ie, RpL35) and RpL35-ligands repurposable drugs artesunate and atazanavir as molecular tools to increase production levels of full-length LAMB3. To evaluate ligand activity in living cells, we monitored artesunate and atazanavir treatment by dual luciferase reporter assays. Production levels of full-length LAMB3 increased up to 200% upon artesunate treatment, up to 150% upon atazanavir treatment, and up to 170% upon combinatorial treatment of RpL35 ligands at reduced drug dosage, with an unrelated PTC reporter being nonresponsive. Proof of bioactivity of RpL35 ligands in selective increase of full-length LAMB3 provides the basis for an alternative, targeted therapeutic route to replenish LAMB3 in severe junctional epidermolysis bullosa.

Schlagwörter

Stichwörter der Autor:innen

Blistering diseaseDrug developmentEpidermolysis bullosaGenetic diseasesGenodermatoses

Autor:innen und Institutionen

  • Department of Biosciences and Medical Biology, University of Salzburg, Salzburg, Austria.
  • Faculty of Pharmacy, College UBT, Prishtina, Kosovo.
  • Institute of Biochemistry, Johannes Kepler University of Linz, Linz, Austria.
  • SKM-IP PartGmbB, Munich, Germany.
  • Merck KGaA, Gernsheim, Germany.
  • ryon-Greentech Accelerator, Gernsheim, Germany.

Förderung

  • Salzburger Landesregierung

Zitieren

APA

Wimmer, B., Friedrich, A., Poeltner, K., Edobor, G., Mosshammer, C., Temaj, G., Rathner, A., Karl, T., Krauss, J., von Hagen, J., Gerner, C., Breitenbach, M., Hintner, H., Bauer, J. W., & Breitenbach-Koller, H. (2024). En Route to Targeted Ribosome Editing to Replenish Skin Anchor Protein LAMB3 in Junctional Epidermolysis Bullosa. JID Innovations, 4(1), 100240. https://doi.org/10.1016/j.xjidi.2023.100240

Vancouver

Wimmer B, Friedrich A, Poeltner K, Edobor G, Mosshammer C, Temaj G, et al. En Route to Targeted Ribosome Editing to Replenish Skin Anchor Protein LAMB3 in Junctional Epidermolysis Bullosa. JID Innovations. 2024;4(1):100240. doi:10.1016/j.xjidi.2023.100240

BibTeX
@article{Wimmer2024,
  author = {Wimmer, Bjoern and Friedrich, Andreas and Poeltner, Katharina and Edobor, Genevieve and Mosshammer, Claudia and Temaj, Gazmend and Rathner, Adriana and Karl, Thomas and Krauss, Jan and von Hagen, Joerg and Gerner, Christopher and Breitenbach, Michael and Hintner, Helmut and Bauer, Johann W and Breitenbach-Koller, Hannelore},
  title = {En Route to Targeted Ribosome Editing to Replenish Skin Anchor Protein LAMB3 in Junctional Epidermolysis Bullosa},
  journal = {JID Innovations},
  year = {2024},
  volume = {4},
  number = {1},
  pages = {100240},
  doi = {10.1016/j.xjidi.2023.100240}
}
Kostenlos starten →